查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722905

2025 年至 2033 年癌症免疫療法市場規模、佔有率、趨勢及預測（按療法類型、應用、最終用戶和地區）

Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球癌症免疫治療市場規模價值 1,295 億美元。展望未來， IMARC Group估計到 2033 年市場規模將達到 2,712 億美元，2025 年至 2033 年的複合年成長率為 8.6%。北美目前佔據市場主導地位，到 2024 年市佔率將超過 45.2%。癌症病例的增加、政府的有利措施以及醫療保險的便利性是推動市場發展的一些關鍵因素。

全球癌症免疫治療市場分析：

主要市場促進因素：由於飲食不均衡和攝取有毒物質導致的癌症病例增加是推動市場成長的主要因素之一。除此之外，世界各地大眾對各種癌症治療方案的認知也不斷提高也促進了市場的成長。

主要市場趨勢：醫療保險的廣泛普及和便捷獲取，以及醫療支出的不斷增加，為行業投資者提供了豐厚的成長機會。除此之外，人們對免疫療法等副作用較少的先進治療方案的青睞也為市場帶來了積極的前景。

地理格局：從區域來看，市場分為北美、亞太、歐洲、拉丁美洲以及中東和非洲，其中北美目前在全球市場佔據主導地位。

競爭格局：全球癌症免疫治療市場的一些領導者包括安進公司、阿斯特捷利康公司、拜耳公司、百時美施貴寶公司、禮來公司、羅氏公司、葛蘭素史克公司、強生公司、默克公司、諾華公司、輝瑞公司、賽諾菲公司和Seagen公司等。

挑戰與機會：不同類型的腫瘤反應不同。然而，在某些情況下，尤其是冷腫瘤，免疫療法沒有反應，這表明存在抗藥性。因此，內在性或後天性抗藥性的產生對於免疫治療領域的市場參與者來說既是一個巨大的挑戰，也是一個巨大的機會。

全球癌症免疫治療市場趨勢

癌症發生率不斷上升

全球癌症病例數量的不斷增加主要推動了癌症免疫療法市場的發展。國際癌症研究機構（IARC）估計，2020年全球癌症病例約1929萬例。預計到 2030 年，這些病例將增加到 2,458 萬例。癌症病例的大幅成長增加了對免疫療法等有效治療方案的需求。根據GLOBOCAN統計，2020年美國約有2,281,658例新發癌症病例，約612,390例死於癌症。除此之外，肺癌和乳癌是個人中最常見的兩種癌症。加拿大癌症協會（CCS）表示，2020年，近29,800名加拿大人被診斷出罹患肺癌，佔所有新增癌症病例的13%。預計約有 21,200 名加拿大人死於肺癌，佔 2020 年所有癌症死亡人數的 25%。這表明對有效且更先進的癌症免疫療法的需求日益成長。因此，對有效和持久的癌症治療的需求不斷增加，預計將為整個市場提供豐厚的成長機會。

新型免疫療法核准率不斷上升

各主要市場參與者正大力投資研發活動，以開發和引進先進、更有效的免疫療法。根據國家臨床試驗 (NCT) 註冊中心的數據，截至 2020 年 9 月 8 日，全球有 1,000 多項臨床試驗正在進行中，旨在開發基於免疫療法的癌症治療。此外，許多國家的政府當局和相關監管機構正在採取措施加快新型免疫療法的核准流程，預計將進一步促進市場成長。例如，根據美國癌症研究協會發表的一篇文章，2023年7月，FDA批准quizartinib（Vanflyta）用於治療新診斷的急性髓性白血病（AML）的不同階段。 Quizartinib 專注於 FLT3，這是一種在約三分之一的 AML 病例中發生扭曲的激酶。同樣，2021年5月，美國FDA批准安進公司的LUMAKRAS（Sotorasib）用於治療KRAS G12C突變的局部晚期或轉移性非小細胞肺癌（NSCLC）患者。 LUMAKRAS 是第一個也是唯一一個針對 NSCLC 的標靶治療方法。預計這些發展將在未來幾年推動癌症免疫治療市場的成長。

製藥公司與研究機構之間的夥伴關係與合作

主要參與者正在採取各種策略性措施來推出新產品，這為整個市場創造了積極的前景。例如，2023年9月，Immatics與Moderna達成策略合作，共同開發腫瘤治療學。此次合作包括對 Immatics 研究性 PRAME203 TCRT 與 Moderna 正在開發的 MARTE mRNA 癌症疫苗的聯合使用進行評估。此外，2023年8月，FBD Biologics Limited與上海復宏漢霖生物科技股份有限公司達成策略合作，共同推動新型免疫療法的研發。同樣，2023年12月，德國研究機構BioMed X宣布與日本製藥公司小野製藥株式會社開展一項新的聯合研究項目，利用中性粒細胞的抗腫瘤作用設計下一代免疫療法。安進公司、阿斯特捷利康公司、拜耳公司和禮來公司等多家市場參與者都參與了併購活動。透過併購活動，這些公司正在擴大其地理覆蓋範圍並進入新的領域。反過來，預計這將在預測期內增加癌症免疫療法市場的收入。

本報告回答的關鍵問題

  • 什麼是癌症免疫療法？癌症免疫治療市場有多大？
  • 2025-2033年全球癌症免疫治療市場的預期成長率是多少？
  • 推動全球癌症免疫治療市場發展的關鍵因素有哪些？
  • 根據治療類型，全球癌症免疫治療市場的主要細分市場是什麼？
  • 根據應用，全球癌症免疫治療市場的主要細分領域是什麼？
  • 根據最終用戶來看，全球癌症免疫治療市場的主要細分市場是什麼？
  • 全球癌症免疫治療市場的主要區域有哪些？
  • 全球癌症免疫治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球癌症免疫療法市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依治療類型

  • 單株抗體
  • 癌症疫苗
  • 檢查點抑制劑
  • 免疫調節劑
  • 其他

第7章：市場區隔：依應用

  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 黑色素瘤
  • 攝護腺癌
  • 頭頸癌
  • 其他

第8章：市場區隔：按最終用戶

  • 醫院
  • 癌症研究中心
  • 診所
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Seagen Inc.
Product Code: SR112025A5095

The global cancer immunotherapy market size was valued at USD 129.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 271.2 Billion by 2033, exhibiting a CAGR of 8.6% from 2025-2033. North America currently dominates the market, holding a market share of over 45.2% in 2024. The growing number of cancer cases, favorable government initiatives, and easy availability of medical insurance represent some of the key factors driving the market.

Global Cancer Immunotherapy Market Analysis:

Major Market Drivers: The increasing cases of cancer on account of a poor balanced diet and consumption of toxic substances is one of the primary factors driving the growth of the market. In addition to this, the growing awareness about various cancer treatment options among the masses across the world is also contributing to the market growth.

Key Market Trends: The wide availability and easy access to medical insurance, along with the increasing healthcare expenditures, is offering lucrative growth opportunities to industry investors. In addition to this, the emerging preference for advanced treatment solutions with fewer side effects, like immunotherapy, is creating a positive outlook for the market.

Geographical Landscape: On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Competitive Landscape: Some of the leading players in the global cancer immunotherapy market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, and Seagen Inc., among others.

Challenges and Opportunities: Different tumor types respond differently. However, in some cases, especially cold tumors immunotherapy is unresponsive, suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge as well as a significant opportunity for the market players in the immunotherapy field.

Global Cancer Immunotherapy Market Trends

Increasing Prevalence of Cancer

The rising number of cancer cases across the world is primarily driving the market for cancer immunotherapies. The International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Such a substantial growth in cancer cases is augmenting the demand for effective treatment solutions like immunotherapies. According to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer immunotherapy. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.

Rising Approval of Novel Immunotherapies

Various key market players are extensively investing in research and development activities to develop and introduce advanced and more effective immunotherapies. According to the National Clinical Trials (NCT) Registry, as of September 8, 2020, there were more than 1,000 ongoing clinical trials across the world for the development of cancer treatment with immune-based therapies. Moreover, government authorities and concerned regulators of numerous nations are taking initiatives to expedite the approval process of novel immunotherapies, which is anticipated to further catalyze the market growth. For instance, according to an article published by the American Association for Cancer Research, in July 2023, the FDA approved quizartinib (Vanflyta) for treating different phases of newly diagnosed acute myeloid leukemia (AML). Quizartinib focuses on FLT3, a kinase that goes twisted in about one-third of AML cases. Similarly, in May 2021, the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with KRAS G12C, which involves mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). LUMAKRAS is the first and only targeted treatment for NSCLC. Such developments are expected to propel the cancer immunotherapy market growth in the coming years.

Partnerships and Collaborations between Pharmaceuticals and Research Institutions

Various Strategic initiatives are being undertaken by major players to launch new products, which is creating a positive outlook for the overall market. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop Oncology Therapeutics. The collaboration includes an assessment of Immatics investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. Similarly, in December 2023, BioMed X, a German research institution, announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils. Several market players, such as Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are involved in merger and acquisition activities. Through M&A activity, these companies are expanding their geographic reach and entering new territories. This, in turn, is projected to bolster the cancer immunotherapy market revenue over the forecasted period.

Key Market Segmentation:

Breakup by Therapy Type:

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • Others

Currently, monoclonal antibodies hold the majority of the total market share

Increasing investment for research and development activities of monoclonal antibodies is opening new avenues for the growth of companies in the oncology therapeutics space. Monoclonal antibodies are extensively being studied for their therapeutic effects against various types of cancers. For instance, in August 2023, FDA approved Talvey to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of treatment, including proteasome inhibitors, immunomodulatory agents and an antiCD38 monoclonal antibody.

Breakup by Application:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Others

Among these, lung cancer currently exhibits a clear dominance in the market

According to cancer immunotherapy market overview, the lung cancer segment accounted for the largest revenue share in the market. This can be attributed to the increasing prevalence of lung malignancies, the escalating adoption of immunotherapy, and the presence of a robust pipeline of investigational candidates. Furthermore, rising product approval and new product launches also providing a positive outlook to the market. For instance, in November 2023, the US Food and Drug Administration (FDA) granted marketing authorizations to Augtyro (Bristol, Inc.) for the treatment of locally refractory or metastatic Non-Small Cell Lung Cancer (NSCLC) with Repotrectinib.

Breakup by End User:

  • Hospitals
  • Cancer Research Centers
  • Clinics
  • Others

Hospitals account for the largest market share

Growing cases of cancer, increasing treatment rates, along with a large number of hospitals offering immunotherapies are contributing to a rise in the number of patients admitted to a hospital. To treat cancer, hospitals are increasingly utilizing immunotherapies. According to an article published by the National Cancer Institute, in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.

Breakup by Regional:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America currently dominates the global market.

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy.

The growth in the region can be attributed to the growing number of patients suffering from cancer, the rising development of bioinformatic tools, and favorable government initiatives. According to GLOBOCAN, in the US, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the year 2020. Moreover, the presence of key players in this region is also contributing to the growth of the market. According to an article published by Elsevier Ltd., in April 2023, the US National Cancer Institute published its expected national cancer plan, a roadmap, and calls to action on improving all stages of care for those suffering from cancer.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • Seagen Inc.

Key Questions Answered in This Report

  • 1.What is cancer immunotherapy?
  • 2.How big is the cancer immunotherapy market?
  • 3.What is the expected growth rate of the global cancer immunotherapy market during 2025-2033?
  • 4.What are the key factors driving the global cancer immunotherapy market?
  • 5.What is the leading segment of the global cancer immunotherapy market based on therapy type?
  • 6.What is the leading segment of the global cancer immunotherapy market based on application?
  • 7.What is the leading segment of the global cancer immunotherapy market based on end user?
  • 8.What are the key regions in the global cancer immunotherapy market?
  • 9.Who are the key players/companies in the global cancer immunotherapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Checkpoint Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunomodulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Breast Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Colorectal Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Melanoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Prostate Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Head and Neck Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cancer Research Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GSK plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Johnson & Johnson
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck KGaA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Sanofi S.A
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Seagen Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2024
  • Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2024
  • Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
  • Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
  • Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million USD), 2025-2033
  • Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
  • Table 7: Global: Cancer Immunotherapy Market: Key Players